Pharmaceutical development and optimization of azithromycin suppository for paediatric use
Pharmaceutical development and manufacturing process optimization work was undertaken in order to propose a potential paediatric rectal formulation of azithromycin as an alternative to existing oral or injectable formulations. The target product profile was to be easy-to-use, cheap and stable in tro...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2013
|
| _version_ | 1826263010401845248 |
|---|---|
| author | Kauss, T Gaubert, A Boyer, C Ba, B Manse, M Massip, S Léger, J Fawaz, F Lembege, M Boiron, J Lafarge, X Lindegardh, N White, N Olliaro, P Millet, P Gaudin, K |
| author_facet | Kauss, T Gaubert, A Boyer, C Ba, B Manse, M Massip, S Léger, J Fawaz, F Lembege, M Boiron, J Lafarge, X Lindegardh, N White, N Olliaro, P Millet, P Gaudin, K |
| author_sort | Kauss, T |
| collection | OXFORD |
| description | Pharmaceutical development and manufacturing process optimization work was undertaken in order to propose a potential paediatric rectal formulation of azithromycin as an alternative to existing oral or injectable formulations. The target product profile was to be easy-to-use, cheap and stable in tropical conditions, with bioavailability comparable to oral forms, rapidly achieving and maintaining bactericidal concentrations. PEG solid solution suppositories were characterized in vitro using visual, HPLC, DSC, FTIR and XRD analyses. In vitro drug release and in vivo bioavailability were assessed; a study in rabbits compared the bioavailability of the optimized solid solution suppository to rectal solution and intra-venous product (as reference) and to the previous, non-optimized formulation (suspended azithromycin suppository). The bioavailability of azithromycin administered as solid solution suppositories relative to intra-venous was 43%, which compared well to the target of 38% (oral product in humans). The results of 3-month preliminary stability and feasibility studies were consistent with industrial production scale-up. This product has potential both as a classical antibiotic and as a product for use in severely ill children in rural areas. Industrial partners for further development are being sought. © 2012 Elsevier B.V. All rights reserved. |
| first_indexed | 2024-03-06T19:44:54Z |
| format | Journal article |
| id | oxford-uuid:21f2c8b2-5ece-483d-bfe2-9f70a2f88d0f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T19:44:54Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:21f2c8b2-5ece-483d-bfe2-9f70a2f88d0f2022-03-26T11:36:08ZPharmaceutical development and optimization of azithromycin suppository for paediatric useJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:21f2c8b2-5ece-483d-bfe2-9f70a2f88d0fEnglishSymplectic Elements at Oxford2013Kauss, TGaubert, ABoyer, CBa, BManse, MMassip, SLéger, JFawaz, FLembege, MBoiron, JLafarge, XLindegardh, NWhite, NOlliaro, PMillet, PGaudin, KPharmaceutical development and manufacturing process optimization work was undertaken in order to propose a potential paediatric rectal formulation of azithromycin as an alternative to existing oral or injectable formulations. The target product profile was to be easy-to-use, cheap and stable in tropical conditions, with bioavailability comparable to oral forms, rapidly achieving and maintaining bactericidal concentrations. PEG solid solution suppositories were characterized in vitro using visual, HPLC, DSC, FTIR and XRD analyses. In vitro drug release and in vivo bioavailability were assessed; a study in rabbits compared the bioavailability of the optimized solid solution suppository to rectal solution and intra-venous product (as reference) and to the previous, non-optimized formulation (suspended azithromycin suppository). The bioavailability of azithromycin administered as solid solution suppositories relative to intra-venous was 43%, which compared well to the target of 38% (oral product in humans). The results of 3-month preliminary stability and feasibility studies were consistent with industrial production scale-up. This product has potential both as a classical antibiotic and as a product for use in severely ill children in rural areas. Industrial partners for further development are being sought. © 2012 Elsevier B.V. All rights reserved. |
| spellingShingle | Kauss, T Gaubert, A Boyer, C Ba, B Manse, M Massip, S Léger, J Fawaz, F Lembege, M Boiron, J Lafarge, X Lindegardh, N White, N Olliaro, P Millet, P Gaudin, K Pharmaceutical development and optimization of azithromycin suppository for paediatric use |
| title | Pharmaceutical development and optimization of azithromycin suppository for paediatric use |
| title_full | Pharmaceutical development and optimization of azithromycin suppository for paediatric use |
| title_fullStr | Pharmaceutical development and optimization of azithromycin suppository for paediatric use |
| title_full_unstemmed | Pharmaceutical development and optimization of azithromycin suppository for paediatric use |
| title_short | Pharmaceutical development and optimization of azithromycin suppository for paediatric use |
| title_sort | pharmaceutical development and optimization of azithromycin suppository for paediatric use |
| work_keys_str_mv | AT kausst pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT gauberta pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT boyerc pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT bab pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT mansem pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT massips pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT legerj pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT fawazf pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT lembegem pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT boironj pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT lafargex pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT lindegardhn pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT whiten pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT olliarop pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT milletp pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse AT gaudink pharmaceuticaldevelopmentandoptimizationofazithromycinsuppositoryforpaediatricuse |